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RESUMO
O novo severe acute respiratory syndrome coronavírus 2 é a causa da doença por coronavírus 2019, uma doença emergente, sem 
tratamento eficaz nem vacina, que alcançou proporções de pandemia. Neste documento, analisamos a forma como as autoridades e 
agências de saúde em todo o Mundo se posicionam em relação ao uso de fármacos off-label ou novos produtos de investigação para 
o tratamento da doença por coronavírus 2019. Revemos os fármacos mais promissores, incluindo a evidência disponível, as recomen-
dações clínicas e as atuais opções de acesso a estes medicamentos. Concluímos enfatizando a importância de administrar fármacos 
em uso off-label e produtos de investigação em contexto de ensaios clínicos, ou pelo menos em circunstâncias padronizadas, para que 
se gere o máximo possível de conhecimento científico a mesmo tempo que se concentram esforços em tratar doentes e salvar vidas.
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ABSTRACT
The novel severe acute respiratory syndrome coronavirus 2 is the cause of coronavirus disease 2019, a new illness with no effective 
treatment or vaccine that has reached pandemic proportions. In this document, we analyze how health authorities and agencies around 
the world position themselves regarding the off-label use of repurposed drugs or new investigational drugs to treat coronavirus disease 
2019. We review the most promising candidate medicines, including available evidence, clinical recommendations and current options 
for access. Our concluding remarks stress the importance of administering off-label and investigational drugs in the setting of clinical 
trials, or at least in standardized scenarios, to generate as much scientific knowledge as achievable while engaging in the best efforts 
to treat patients and save lives.
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INTRODUCTION
 We overcame two epidemics by Coronavirus (CoV) 
in our recent history: severe acute respiratory syndrome 
(SARS) caused by SARS CoV in 2003 and Middle East 
respiratory syndrome (MERS) caused by MERS Novel CoV 
(MERS-CoV) in 2013. Fortunately, these epidemics were 
contained, but not thanks to pharmacological interventions, 
though. In fact, the scientific community left behind these 
two menaces to global health empty-handed: no effective 
treatment and no vaccine. Although numerous therapies 
were tested, no new drugs emerged, in part because most 
studies were uncontrolled, single-arm observations and 
case series.1
 A new epidemic of CoV was first noted in December 
2019 in Wuhan, Hubei province, China.2 This CoV was 
named novel SARS coronavirus 2 (SARS-CoV-2) and the 
infection Coronavirus Disease 2019 (COVID-19). COVID-19 
was declared a pandemic by the World Health Organization 
on the 11th March 2020.3 By Easter time in 2020, more than 
1.5 million cases of COVID-19 had been reported in over 
213 countries and territories, resulting in close to 100 000 
deaths.4
NATIONAL AND INTERNATIONAL USE OF MEDICINES 
TO TREAT COVID-19
 China was the first country to take its toll in the 
COVID-19 pandemic with more than 80 000 confirmed 
cases and over 3000 reported deaths.4 Alone in the first re-
sponse to COVID-19, China was quick to elaborate national 
guidelines for the treatment of COVID-19. Based on data 
from in vitro studies, case series and small uncontrolled 
trials from the SARS-CoV and MERS-CoV epidemics, the 
proposed treatments included lopinavir/ ritonavir (LPV/r), 
remdesivir, ribavirin, interferon beta, chloroquine (CQ) and 
hydroxychloroquine (HCQ), tocilizumab, intravenous immu-
noglobulin, convalescent plasma and Traditional Chinese 
Medicine.5 China was responsible for the dissemination of 
most of the currently available clinical data but unfortunately 
this information mostly stems from observational studies, 
single-arm interventions, which are uncontrolled and under-
powered to provide good quality scientific knowledge. 
 Despite the low level of evidence, considering the ur-
gency and the pressure healthcare systems face to save 
lives during the COVID-19 pandemic, some countries, in-
cluding Portugal, the USA, France and Spain, have issued 
recommendations and protocols to allow the use of some of 
these drugs in patients with severe forms of COVID-19.6–9 In 
Portugal,  the Directorate-General of Health (DGS) guide-
line on the management of patients with COVID-19 states 
that, although no drugs are approved for the treatment of 
COVID-19), in severe cases (pneumonia or critical disease) 
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clinicians may consider the use of HCQ, LPV/r or remdesi-
vir.6
 The World Health Organization (WHO) displays a prag-
matic perspective reinforcing there is no current evidence to 
recommend any specific anti-COVID-19 treatment and rec-
ommending that the use of investigational anti-COVID-19 
medicines should be done under ethically approved, rand-
omized, controlled trials.10
 The European Medicines Agency (EMA) adopted a simi-
lar position and advised healthcare professionals to only use 
medicines, particularly CQ and HCQ, for their authorized 
indications or as part of clinical trials or national emergency 
use programs for the treatment of COVID-19.11 In Portugal, 
the latest guidance from the Portuguese national medicines 
agency (Infarmed) on access to experimental therapies for 
COVID-19 starts by stressing the current absence of drugs 
approved for COVID-19, goes on to review the existing evi-
dence for remdesivir, LPV/r and HCQ, lists ongoing clinical 
trials and ends stating the access to these drugs is very 
limited and dependent on an exceptional use authorization, 
according to the National Law on Human Medicines Use.12
 In the United States, the Centers for Disease Control 
and Prevention (CDC) are aligned with the WHO posi-
tion,7 but the national medicines agency Food and Drug 
Administration (FDA) issued CQ and HCQ an emergency 
use authorization to add the drug to the Strategic National 
Stockpile, thus allowing doctors to use it in cases they deem 
critical.13 This happened on the aftermath of president Don-
ald Trump enthusiastically referring to HCQ as a ‘phenom-
enal drug’, and ‘the biggest game changer in the history of 
medicine’,14 after a study from France showed encourag-
ing results for the combination of HCQ and azithromycin in 
COVID-19 treatment.15
MEDICINES CURRENTLY CONSIDERED FOR THE 
TREATMENT OF COVID-19
 An array of drugs approved for other indications as well 
as several investigational drugs are being studied in clinical 
trials that are underway across the globe.16
 Based on currently available evidence, we will be focus-
ing on the more promising candidate drugs being evaluated 
in humans infected with SARS-CoV-2 aimed at reducing mor-
tality and disease progression: CQ and HCQ, LPV/r, remde-
sivir and tocilizumab. Briefly, we will mention other therapeu-
tic options such as convalescent plasma and corticosteroids. 
In the Appendix (see Appendix 1: https://www.actamedica-
portuguesa.com/revista/index.php/amp/article/view/13908/ 
Appendix_01.pdf), we provide a summary of the most rele-
vant evidence from key clinical trials and observational 
studies on treatment of COVID-19. 
Chloroquine and hydroxychloroquine
 CQ and HCQ are antimalarial agents currently used for 
the treatment of malaria and autoimmune diseases such as 
lupus and rheumatoid arthritis. These drugs have demons-
trated antiviral effects on SARS-CoV and SARS-CoV-2 
in vitro: these drugs are believed to act on the entry and 
post-entry stages of SARS-CoV and SARS-CoV-2 infec-
tion, likely via effects on endosomal pH and the resulting 
under-glycosylation of angiotensin-converting enzyme 2 
receptors that are required for viral entry.17 However, no ef-
fective activity for any viral infection has been shown in vivo, 
including animal models for Ebola virus or in humans for 
influenza and HIV.18 Both CQ and HCQ have known safety 
profiles with the main concerns for short term use being 
acute cardiotoxicity, including prolonged QT syndrome and 
the potential for ventricular arrhythmia. Despite the scant 
evidence, CQ and HCQ were widely used for treatment of 
COVID-19 in China5 resulting in several uncontrolled case 
series and two COVID-19 small randomized clinical trials 
reporting conflicting results: there was no benefit in a 30-pa-
tient study, and a 62-patient trial showed reduced time to 
clinical recovery.19,20
 HCQ, which has a better safety profile than CQ and is 
more widely available, received recently a boost in its use 
worldwide, after a small French study reported that hy-
droxychloroquine alone or in combination with azithromycin 
reduced detection of SARS-CoV-2 RNA in upper respira-
tory tract specimens in 20 patients compared with a non-
randomized control group of 16 patients.15 This study, which 
inspired president Trump’s praise of HCQ14, received heavy 
criticism by peers for being methodologically flawed: small 
sample, lack of patients with severe illness, lack of blind-
ing, no randomization, loss to follow-up, no clinical out-
comes, no correlation between viral carriage and clinical 
outcomes, and conclusions not supported by the reported 
results.21,22 Microbiologist Didier Raoult and his team from 
Marseille then carried out a larger trial of 80 patients treated 
with HCQ and azithromycin, claiming clinical improvement 
and a faster reduction in viral carriage23 – but there was no 
control group and thus it seems problematic to attribute the 
observed results to the intervention. More recently, a pa-
per from France posted on the preprint server medRxiv ex-
amined the medical records of 84 patients with COVID-19 
requiring oxygen who received hydroxychloroquine and 97 
similar patients who did not get the drug. Transfer to inten-
sive care or death from any cause within seven days did not 
differ significantly between the groups. The researchers say 
the findings “do not support the use of [hydroxychloroquine] 
in patients hospitalized for a documented SARS-CoV-2 
pneumonia”.24
 Recently, the American Heart Association, American 
College of Cardiology, and Heart Rhythm Society have is-
sued recommendations on the use of hydroxychloroquine 
and azithromycin to treat COVID-19 in patients with pre-
existing cardiovascular disease, reminding the effects of 
these two drugs in combination on QT prolongation and ar-
rhythmia have not been studied. There is a possible addi-
tive effect, with complications including severe arrhythmia, 
polymorphic ventricular tachycardia, long QT syndrome, 
and increased risk for sudden death.25 In April, the EMA 
warned CQ and HCQ were only to be used in clinical tri-
als or emergency use programs11 and an editorial in The 
BMJ also alerted to the premature and potentially harmful 
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use of these drugs.26 Nevertheless, CQ and HCQ are cur-
rently presented as an option for treatment of hospitalized 
COVID-19 patients in several countries, including the Unit-
ed States,27 France8 and Portugal.6,28 HCQ is currently un-
der investigation in clinical trials worldwide but results are 
not yet available.29 The WHO randomized multicenter adap-
tive Solidarity Trial includes a HCQ arm, and so does the 
European French-initiated Discovery Trial.30,31
Lopinavir/Ritonavir
 Various antivirals are being trialed in patients with 
COVID-19 (e.g., oseltamivir, lopinavir/ritonavir, ganciclovir, 
favipiravir, baloxavir marboxil, umifenovir, interferon alfa)32. 
However, there are no data to support their use.10 LPV/r is 
a combination of antiretroviral protease inhibitors used for 
the treatment of human immunodeficiency virus (HIV) in-
fection. The drug has a generally good safety profile, but 
may have interactions with many drugs commonly used in 
critically ill patients.33 LPV/r also has the potential for un-
wanted QT interval prolongation, and a risk of drug induced 
sudden cardiac death.34 It has weak in vitro activity against 
SARS-CoV-2 and MERS-CoV and was already being test-
ed in combination with interferon beta 1b for the treatment 
of MERS.35 It was extensively used in China for treatment of 
COVID-19 in adult and pediatric populations.5 The only ran-
domized clinical trial so far included LPV/r versus placebo 
(plus standard of care) but it did not show promise for treat-
ment of hospitalized COVID-19 patients with pneumonia 
in China, although we can argue that the lack of evidence 
could relate to its lack of power.36 Although guidelines from 
the US admit a weak recommendation against the routine 
use of lopinavir/ritonavir in critically ill COVID-19 patients,7,33 
the drug is being used in several countries. To clarify the 
role of this antiviral in the treatment of COVID-19, LPV/r 
(with and without interferon beta) is under investigation in 
the WHO-sponsored Solidarity Trial and also in the Discov-
ery Trial.30,31
Remdesivir
 Remdesivir is an investigational broad-spectrum antivi-
ral agent with in vitro activity against multiple RNA viruses, 
including Ebola and CoV.17,37 It is a nucleotide-analog in-
hibitor of RNA-dependent RNA polymerases and requires 
intravenous administration. Remdesivir was considered by 
the WHO as the most promising candidate based on the 
broad antiviral spectrum, the in vitro and in-vivo data avail-
able for coronaviruses and the extensive clinical safety 
database coming from a clinical trial on Ebola virus dis-
ease.38 Nevertheless, this is a drug that has not been pre-
viously approved for clinical use and could cause serious 
adverse effects that were not previously detected because 
of the very small number of exposed patients. Several 
randomized clinical trials, mostly manufacturer-sponsored 
but also the aforementioned Solidarity Trial and Discov-
ery Trial, are currently recruiting patients with COVID-19. 
In addition to clinical trials, the manufacturer of remdesivir 
also has a compassionate-use program, although access is 
currently limited due to shortage of the drug resulting from 
overwhelming demand.39 The results of compassionate-
use were published in the New England Journal of Medi-
cine: among a cohort of 53 patients hospitalized for severe 
COVID-19 who received the drug, most improved, but there 
was no comparison group.40 On the 29th April 2020, the 
National Institutes of Health reported preliminary findings 
from a randomized, placebo-controlled trial of intravenous 
remdesivir (the Adaptive COVID-19 Treatment Trial) in 1063 
patients hospitalized with COVID-19 with lung involvement. 
An interim analysis found that patients recovered faster with 
remdesivir than with placebo. Results also suggested a sur-
vival benefit.41
 Remdesivir is currently the most promising drug in clini-
cal trials for COVID-19. Further results are expected soon, 
as is FDA’s authorization for remdesivir for treatment of 
COVID-19. Meanwhile, physicians around the globe are 
hopeful and trying to access the drug through clinical trials 
or compassionate use.
Tocilizumab
 Tocilizumab is an anti-interleukin 6 (IL-6) monoclonal 
antibody approved for the treatment of rheumatoid arthritis 
and giant cell arteritis. IL-6 inhibitors may cause profound 
immunosuppression, increasing the risk of sepsis, bacte-
rial pneumonia, gastrointestinal perforation, and hepa-
totoxicity.42 The rationale for its use is that patients with 
COVID-19 have elevated levels of the pro-inflammatory cy-
tokine IL-6, with the most severely ill patients exhibiting the 
highest levels.43 It was approved in China to treat patients 
with the severe form of the disease and elevated IL-6 lev-
els. 5 In the rest of the world, health agencies, including the 
WHO, and guidelines have not taken a stance on the use of 
tocilizumab in COVID-19 due to insufficient evidence.7,10,27,33 
Clinical trials are ongoing and spanning the United States, 
Canada, China, and Europe.44 Meanwhile tocilizumab is be-
ing used in more or less controlled scenarios in hospitals 
around the world.
Other therapeutic options
 Convalescent plasma obtained from donors recovered 
from COVID-19 has emerged as a potential therapy by pro-
viding passive immunity via SARS-CoV2-specific antibo-
dies. 
 Over the past two decades, convalescent plasma thera-
py was successfully used in the treatment of SARS, MERS, 
and 2009 H1N1 pandemic with satisfactory efficacy and 
safety.35 Two small case series from China showed prom-
ise for using convalescent plasma to treat critically ill and 
severe patients with COVID-19, improving the clinical out-
comes through neutralizing viremia.45,46 Recently, the FDA 
allowed physicians to apply for emergency use of investi-
gational convalescent plasma to treat individual patients.47 
Currently, most recommendations do not support its routine 
use in critically- or severely-ill patients.33,48
 Evidence suggests that corticosteroids in patients with 
SARS and MERS showed no survival benefit and possible 
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harm,5 although a small retrospective observational study 
suggested that in patients with COVID-19 pneumonia who 
developed acute respiratory distress syndrome (ARDS) 
methylprednisolone appeared to reduce the risk of death.49 
At present, WHO and CDC recommend that corticosteroids 
should not be routinely used in patients with COVID-19 for 
treatment of viral pneumonia or ARDS unless indicated for 
another reason (e.g., asthma or chronic obstructive pulmo-
nary disease exacerbation, septic shock).7,10 
CONCLUSION
 Clinicians in more than 200 countries every day face 
severely-ill patients with COVID-19 and witness thousands 
of deaths feeling desperate and powerless. They have to 
decide whether to administer a therapy and therefore need 
guidance. 
 At the time of this writing, no proven specific therapies 
are available, other than supportive care, and there is mini-
mal evidence from clinical trials to support recommenda-
tions for the use of any specific pharmacological treatment 
for patients with COVID-19. National authorities around the 
globe have offered more or less open access to off-label an-
ti-COVID-19 drugs, with authorization based on ‘emergency 
use’ and relying on clinical judgment. Scientific societies 
have released interim guidelines that are consensual only 
in stressing the lack of evidence of benefit and providing 
weak recommendations for the use of a few drugs reserved 
for the most severe patients. 
 There is an emergent need for information, but informa-
tion must be accurate and evidence-based. Ideally, every 
patient being treated for COVID-19 should be enrolled in 
an ethically-approved, randomized, controlled clinical trial. 
When a trial is unavailable, individual patients may be of-
fered investigational therapeutics on an emergency basis 
but standardized data need to be collected. 
 In the urge to save lives and do one’s best, clinicians 
must always be reminded: the only way we will overcome 
this pandemic with an effective and safe medicine for 
COVID-19 is if we generate scientific knowledge at the 
same time as we are treating the patients.
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